MetaCap

Lyell Immunopharma Insider Trades

NASDAQ: LYELHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.80+0.22 (+1.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
4 · $75.00M
Sales
29 · $612.75K
Shares bought / sold
5.62M / 31.57K
Net activity
Net buying $74.4 million

Lyell Immunopharma insider activity

Over the last 12 months, Lyell Immunopharma insiders reported 41 transactions on SEC Form 4: 4 open-market purchases and 29 sales. Insiders bought $75.0 million and sold $612,747 worth of stock, for net insider buying of $74.4 million. The largest seller was Seely Lynn, with $355,124 in reported sales.

The most recent filing shows Lee Gary K. (Chief Scientific Officer) selling 129 shares at $15.93 on Nov 10, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put LYEL's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

LYEL insider transactions

Lyell Immunopharma insider transactions
DateInsiderTypeSharesValueFiling
Nov 10, 2026Bulis Veronica SanchezVP, Corporate ControllerSale416$6.63KForm 4
Nov 10, 2026Seely LynnPresident and CEOSale545$8.68KForm 4
Nov 10, 2026Hill Stephen J.Chief Operating OfficerSale88$1.40KForm 4
Nov 10, 2026Lee Gary K.Chief Scientific OfficerSale129$2.05KForm 4
Nov 4, 2026ARCH Venture Partners IX, LLC & ARCH Venture Fund IX, L.P. & ARCH Venture Partners IX, L.P. & ARCH Venture Fund IX Overage, L.P. & ARCH Venture Partners IX Overage, L.P.10% OwnerBuy2,321,262$25.00MForm 4
Nov 4, 2026ARCH Venture Fund XIII, L.P. & ARCH Venture Partners XIII, L.P. & ARCH Venture Partners XIII, LLC & CRANDELL KEITH & GILLIS STEVEN & NELSEN ROBERT & Burow Kristina & BERNS PAUL L & BYBEE CLINTON10% OwnerBuy2,321,262$25.00MForm 4
Oct 12, 2026Aguirre Jarrad MattieuChief Medical OfficerSale422$3.64KForm 4
Sep 10, 2026Shook DavidChief Medical OfficerSale500$6.35KForm 4
Aug 21, 2026Lee Gary K.Chief Scientific OfficerSale1,457$22.64KForm 4
Aug 21, 2026Hill Stephen J.Chief Operating OfficerSale989$15.37KForm 4
Aug 21, 2026Seely LynnPresident and CEOSale9,589$149.01KForm 4
Aug 10, 2026Hill Stephen J.Chief Operating OfficerSale89$1.28KForm 4
Aug 10, 2026Lee Gary K.Chief Scientific OfficerSale131$1.88KForm 4
Aug 10, 2026Seely LynnPresident and CEOSale390$5.59KForm 4
Aug 10, 2026Bulis Veronica SanchezVP, Corporate ControllerSale621$8.91KForm 4
Jul 27, 2026Innovative Cellular Therapeutics Holdings Ltd10% Ownerother38,500—Form 4
Jul 27, 2026Innovative Cellular Therapeutics Holdings Ltd10% Ownerother44,000—Form 4
Jul 17, 2026Innovative Cellular Therapeutics Holdings Ltd10% OwnerSale10$137Form 4
Jul 16, 2026Innovative Cellular Therapeutics Holdings Ltd10% OwnerSale10$137.30Form 4
Jun 29, 2026Innovative Cellular Therapeutics Holdings Ltd10% Ownerother76,000—Form 4
Jun 15, 2026Innovative Cellular Therapeutics Holdings Ltd10% Ownerother66,500—Form 4
Jun 10, 2026Shook DavidChief Medical OfficerSale1,977$24.99KForm 4
May 11, 2026Lee Gary K.Chief Scientific OfficerSale130$2.46KForm 4
May 11, 2026Seely LynnPresident and CEOSale388$7.34KForm 4
May 11, 2026Bulis Veronica SanchezVP, Corporate ControllerSale217$4.10KForm 4
May 11, 2026Hill Stephen J.Chief Operating OfficerSale89$1.68KForm 4
Mar 6, 2026ARCH Venture Fund XIII, L.P. & ARCH Venture Partners XIII, L.P. & ARCH Venture Partners XIII, LLC & CRANDELL KEITH & NELSEN ROBERT & Burow Kristina & GILLIS STEVEN & BERNS PAUL L & BYBEE CLINTON10% OwnerBuy488,090$12.50MForm 4
Mar 6, 2026ARCH Venture Partners IX, LLC & ARCH Venture Partners IX, L.P. & ARCH Venture Partners IX Overage, L.P. & ARCH Venture Fund IX, L.P. & ARCH Venture Fund IX Overage, L.P.10% OwnerBuy488,090$12.50MForm 4
Feb 11, 2026Lee Gary K.Chief Scientific OfficerSale1,671$39.08KForm 4
Feb 11, 2026Seely LynnPresident and CEOSale7,455$174.37KForm 4
Feb 11, 2026Hill Stephen J.Chief Operating OfficerSale1,236$28.91KForm 4
Feb 10, 2026Bulis Veronica SanchezVP, Corporate ControllerSale254$5.87KForm 4
Feb 10, 2026Bulis Veronica SanchezVP, Corporate ControllerAward8,750—Form 4
Feb 10, 2026Lee Gary K.Chief Scientific OfficerSale147$3.40KForm 4
Feb 10, 2026Hill Stephen J.Chief Operating OfficerSale109$2.52KForm 4
Feb 10, 2026Seely LynnPresident and CEOSale438$10.13KForm 4
Feb 9, 2026Lee Gary K.Chief Scientific OfficerAward4,000—Form 4
Feb 9, 2026Hill Stephen J.Chief Operating OfficerAward4,000—Form 4
Feb 9, 2026Seely LynnPresident and CEOAward20,000—Form 4
Dec 30, 2025Bulis Veronica SanchezVP, Corporate ControllerSale936$30.25KForm 4
Dec 24, 2025Bulis Veronica SanchezVP, Corporate ControllerSale1,136$43.93KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related